Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 7679 results

  1. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  5. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable ID 6272

      Status ...

    Health technology evaluations
    Topic selection

  6. Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse TS ID 11900

      Status ...

    Health technology evaluations
    Topic selection

  7. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development [GID-TA10486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969

      Status ...

    Technology appraisal guidance
    Topic selection

  9. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  10. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    Awaiting development [GID-TA11341] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development [GID-TA11224] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Cor-Knot for tying suture knots in valve surgery

      Status ...

    Medical technologies guidance
    Topic selection

  15. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

      Status ...

    Medical technologies guidance
    Topic selection